Login
From:
Labiotech.eu
(Uncensored)
subscribe
CatalYm’s monoclonal antibody visugromab bags $150M
https://www.labiotech.eu/trends-news/catalym-visugromab-bags-150m-cancer-therapy-resistance/
links
backlinks
Tagged with:
cancer
germany
funding
immunotherapy
news and trends
On its way to tackle cancer therapy resistance with its monoclonal antibody visugromab, CataLym completes a $150 million series D round.
Roast topics
Find topics
Find it!
